Hyperoside mediates protection from diabetes kidney disease by regulating ROS‐ERK signaling pathway and pyroptosis
Phytotherapy Research · 2023-12 · 37 (12) · 5871-5882
DOI: 10.1002/ptr.7993 ↗At a glance
Journal article in Phytotherapy Research, published online on 2023-08-30. Written by Kejia Zhang and 8 co-authors. Institution: Public Experimental Research Center, Xuzhou Medical University, Xuzhou, China. Major MEDLINE topics: Diabetic Nephropathies, Diabetes Mellitus, Type 2. Cited 23 times so far (Crossref); 28 references. Funded by: National Natural Science Foundation of China, Jiangsu Training Program of Innovation and Entrepreneurship for Undergraduates.
Topics: Diabetes mellitus
Abstract (original language)
Renal tubular injury is a key factor in the progression of diabetic kidney disease to end‐stage renal disease. Hyperoside, a natural flavonol glycoside in various plants, is a potentially effective drug for the clinical treatment of diabetic kidney disease. However, the specific mechanisms remain unknown. Therefore, this study will explore the effect and mechanism of hyperoside on renal tubulointerstitium in diabetic kidney disease. db/db mouse (C57BL/KsJ) is a model of type 2 diabetes resulting from Leptin receptor point mutations, with the appearance of diabetic kidney disease. Therefore, db/db mice were used for in vivo experimental studies. In vitro, human renal tubular epithelial cells were incubated with bovine serum albumin to simulate the injury of renal tubular epithelial cells caused by excessive albumin in primary urine. The experimental results showed that hyperoside could improve kidney function and reduce kidney tissue damage in mice, and could inhibit oxidative stress, extracellularly regulated protein kinases 1/2 signaling activation, and pyroptosis in human renal tubular epithelial cells. Therefore, hyperoside inhibited oxidative stress by regulating the activation of the extracellularly regulated protein kinases 1/2/mitogen‐activated protein kinase signaling pathway, thereby alleviating proteinuria‐induced pyroptosis in renal tubular epithelial cells. This study provides novel evidence that could facilitate the clinical application of hyperoside in diabetic kidney disease treatment.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Public Experimental Research Center, Xuzhou Medical University, Xuzhou, China.
- Department of Pathophysiology, Xuzhou Medical University, Xuzhou, China.
- Laboratory of Clinical and Experimental Pathology, Xuzhou Medical University, Xuzhou, China.
- The Second Clinical Medical School, Xuzhou Medical University, Xuzhou, China.
- Department of Physiology, Xuzhou Medical University, Xuzhou, China.
ORCID profiles: Kejia Zhang, Kaiwen Yin, Minjie Wang, Qiuchi Dong, Zilan Miao, Yubo Guan, Qi Wu, Yao Zhou
Funding
- National Natural Science Foundation of China
- Jiangsu Training Program of Innovation and Entrepreneurship for Undergraduates
Cite
APA
Zhang, K., Li, M., Yin, K., Wang, M., Dong, Q., Miao, Z., Guan, Y., Wu, Q., & Zhou, Y. (2023). Hyperoside mediates protection from diabetes kidney disease by regulating ROS‐ERK signaling pathway and pyroptosis. Phytotherapy Research, 37(12), 5871-5882. https://doi.org/10.1002/ptr.7993
Vancouver
Zhang K, Li M, Yin K, Wang M, Dong Q, Miao Z, et al. Hyperoside mediates protection from diabetes kidney disease by regulating ROS‐ERK signaling pathway and pyroptosis. Phytotherapy Research. 2023;37(12):5871-5882. doi:10.1002/ptr.7993
BibTeX
@article{Zhang2023,
author = {Zhang, Kejia and Li, MiaoMiao and Yin, Kaiwen and Wang, Minjie and Dong, Qiuchi and Miao, Zilan and Guan, Yubo and Wu, Qi and Zhou, Yao},
title = {Hyperoside mediates protection from diabetes kidney disease by regulating ROS‐ERK signaling pathway and pyroptosis},
journal = {Phytotherapy Research},
year = {2023},
volume = {37},
number = {12},
pages = {5871--5882},
doi = {10.1002/ptr.7993}
}
EUVIMED